

- JC virus infection
 in cancer patient, 488t, 490
 in HIV infection, 1266
 in progressive multifocal leukoencephalopathy, 899, 1962, 2669
 in transplant recipient, 923, 925, 1831
- Jefferson fracture, 441e-32f
- Jejunal vascular ectasia, 1883f, 1897f
- Jejunostomy tube feeding, 98e-8t, 261
- Jellyfish sting, 2738–2739, 2741f
- Jerk nystagmus, 210
- Jervell and Lange-Nielsen syndrome, 220, 222t, 444e-2t
- Jet lag disorder, 194
- Jigger, 2750
- Jimson weed, 473e-9t
- JK bacillus infection, 486t
- JMML (juvenile myelomonocytic leukemia), 135e-6
- Job's syndrome. *See* Hyper-IgE syndrome
- Jod-Basedow effect, 2300, 2302
- Joint(s)
 disorders of. *See* Arthritis; Musculoskeletal disorders; Osteoarthritis
 failure of, 2226–2227, 2227f
 malalignment of, 2221, 2228, 2228f
 in nutritional deficiencies, 463t
 position testing, 159, 160t
 prosthetic, infections in. *See* Prosthetic joint infections
 protective mechanisms of, 2226–2227
- Joint Commission, infection-control guidance and oversight, 911–912
- Joint replacement, 2233. *See also* Knee replacement
- Joint United Nations Program on HIV/AIDS (UNAIDS), 8, 12
- Jones criteria, 2152, 2152t
- Josamycin, 1157
- Joubert's syndrome, 451e-4t, 1851f, 1855
- JPH3* gene mutations, 2622
- Jugular septic thrombophlebitis. *See* Lemierre's disease/syndrome
- Jugular venous pressure
 in heart failure, 286, 1504
 in hypovolemia, 298
 measurement of, 1443–1444, 1444f
 in shock, 1729
- Jumper's knee, 2220–2221
- Junctional bradycardia, ECG in, 278e-3f
- Junctional tachycardia, 1480–1481
- JUN* gene mutations, 101e-2t
- Junín/Argentinian hemorrhagic fever, 1320
- Junín virus, 1306t
- Juquitiba virus, 1308t
- Justice, 17e-2
- Juvenile arthritis, 373e-7–8
- Juvenile arthritis, HLA gene association with, 373e-8t
- Juvenile goiter, 2301
- Juvenile granulosa tumors, 594
- Juvenile myelomonocytic leukemia (JMML), 135e-6
- Juvenile myotonic epilepsy, 2544
- Juvenile-onset spondyloarthritis, 2178
- Juvenile Paget's disease, 426e-1
- Juvenile polyposis, 101e-6t, 538t
- Juvenile polyps, 537
- Juxtaglomerular apparatus, 332e-2f
- K**
- K8/18 (keratins 8 and 18), 2056
- KAL1* gene mutations, 2256, 2363, 2364t
- Kala-azar, 245e-2, 245e-4t. *See also* Visceral leishmaniasis
- Kallmann syndrome, 215, 2256, 2363
- Kanagawa phenomenon, 1065
- Kanamycin, 205e-6, 930, 937t, 942
- Kaolin-pectin, 41, 246e-1t
- Kaposi's sarcoma
 clinical features of, 76e-5f, 364t, 367, 1268–1269, 1269f
 diagnosis of, 1269
 epidemiology of, 1242
- etiology of, 502, 1242
- HHV-8 infection and, 119e-1, 214e-7, 1194
- in HIV infection, 1268–1269, 1269f, 1269t, 1270t
- opharyngeal, 240t
- pathogenesis of, 1242
- pericardial, 1255
- staging of, 1269, 1269t
- in transplant recipient, 924, 925
- treatment of, 1269–1270, 1270t
- Kaposi's sarcoma-associated herpesvirus (KSHV)
 infection. *See* Human herpesvirus-8 (HHV-8) infection
- Kappa receptors, 468e-1t
- Karnofsky Performance Scale, 472, 472t
- Karyomegalic tubulointerstitial nephritis, 1855, 1861
- Karyorrhexis, 102e-8
- Katayama syndrome, 1425, 1427
- katG* gene, 1106
- Kava, 43, 283
- Kawasaki disease
 clinical features of, 130t, 134, 363
 epidemiology of, 2192
 prognosis of, 2193
 rash in, 25e-7f, 130t, 362t, 363
 treatment of, 2193
 vasculitis in, 2192–2193
- Kayser-Fleischer ring, 436e-8f, 2519, 2520f, 2520t, 2625
- KCl. *See* Potassium chloride (KCl)
- KCNH2* gene mutations, 1496t
- KCNJ5* gene mutations, 306
- KCNJ18* gene, 462e-18
- KCNQ1* gene mutations, 1496t
- KCNQ2* gene mutations, 2545t
- Kearns-Sayre syndrome (KSS), 451e-3t
 clinical features of, 85e-6, 85e-6t, 462e-15, 2483
 AV conduction block, 1471, 1471t
 endocrine, 2324t, 2348
 ocular, 206, 207
 SA node dysfunction, 1467, 1467t
 diagnosis of, 462e-15
 genetic considerations in, 451e-3t, 462e-15, 2324t
 mitochondrial DNA mutation in, 85e-6, 85e-6t, 462e-15, 2348
 treatment of, 462e-15
- Kegel exercises (pelvic muscle exercises), 81
- Kell blood group system, 138e-1t, 138e-2
- Kelley-Seegmiller syndrome, 431e-5
- Kelling-Madlener procedure, 1926
- Keloid, 76e-4f, 341t
- Kemerovo virus, 1308t
- Kennedy's disease. *See* Spinobulbar muscular atrophy (Kennedy's disease)
- Kenney-Caffey syndrome, 2483
- Kenya tick typhus, 1157
- Keratic precipitates, 200
- Keratin, 372e-24t
- Keratinocyte(s), 386
- Keratinocyte growth factor therapy, for mucositis, 103e-25
- Keratins 8 and 18 (K8/18), 2056
- Keratitis, 200–201
Acanthamoeba, 1368, 1368f
Aspergillus, 1348
Fusarium, 1355–1356
HSV, 200, 215e-9, 1178, 1182t
Nocardia, 1086, 1087, 1087t
Oncocerca, 1421
P. aeruginosa, 1045t, 1046
 pigmented mold, 1355
Scedosporium, 1356
- Keratoacanthoma, 76e-6f, 501, 501f
- Keratoconjunctivitis, 199–200, 1208
- Keratoconjunctivitis sicca (dry eye)
 clinical features of, 199
 diagnosis of, 2166
 differential diagnosis of, 2167t
 etiology of, 199
 in sarcoidosis, 2207
 in Sjögren's syndrome, 2166, 2167t
- in SLE, 2129t, 2131
- in systemic sclerosis, 2162
- treatment of, 199, 2168f, 2169
- Keratoderma blenorrhagica, 2174
- Keratolytic agents, 351
- Keratomalacia, 96e-6
- Keratosis pilaris, 341t, 342f
- Kerion, 350, 355t
- Kerley B lines, 476e-3, 1552
- Kernicterus, 2001t, 2002
- Kernig's sign, 883
- Kernohan-Woltman sign, 1772
- Keshan's disease, 96e-10, 1563
- Ketamine
 abuse of, 168, 469e-5
 adverse effects of, 1741
 antidepressant effects of, 465e-2, 2717
 over dosage/poisoning with, 473e-3
 for sedation during mechanical ventilation, 1741
- Ketanserin, 566
- Ketoacidosis
 alcoholic, 299, 318–319
 breath odor in, 242
 diabetic. *See* Diabetic ketoacidosis (DKA)
 nausea and vomiting in, 259
- α -Ketoadipic acidemia, 434e-3t
- Ketoconazole
 for adrenal blockade in breast and prostate cancer, 103e-16
 adverse effects of, 246e-3t, 310, 2273
 for *Blastomyces* infections, 1339t
 for candidiasis, 233
 for Cushing's syndrome, 2273, 2318
 for cutaneous leishmaniasis, 1393
CYP3A and, 34t, 42t
 drug interactions of, 34t, 42t, 246e-3t, 328, 1590, 1921
 for ectopic ACTH syndrome, 611
 for hypercalcemia, 314
 for male precocious puberty, 2362
 in pregnancy and lactation, 246e-3t
 for seborrheic dermatitis, 347
 shampoo, for tinea, 355t
 for tinea versicolor, 350
- Ketolides, 931, 931t, 934. *See also* Telithromycin
- Ketoprofen, 338
- Ketorolac, 91, 91t, 199, 478e-4t, 635
- Khat leaves, 469e-3–4
- KI. *See* Potassium iodide (KI)
- Ki-67, 560, 2322
- Kidd blood group system, 138e-1t, 138e-2
- Kidney. *See also* Nephron(s)
 calcium absorption/excretion by, 2457
 congenital abnormalities of, 333e-1, 1855
 disease/failure
 acute. *See* Acute kidney injury (AKI)
 chronic. *See* Chronic kidney disease (CKD)
 glomerular. *See* Glomerular diseases
 nephrolithiasis. *See* Nephrolithiasis
 tubulointerstitial diseases. *See* Tubulointerstitial diseases
 vascular. *See* Renovascular disease
 drug clearance in, 935
 embryological development of, 332e-1–2, 332e-1f, 333e-1
 erythropoietin production in, 392, 392f
 hypoplastic, 333e-1
 in hypothermia, 478e-2t
 ischemic preconditioning in, 333e-3–4, 333e-4t
 phosphate absorption/excretion by, 2458
 potassium absorption/excretion by, 64e-2f, 304–305, 332e-5f, 332e-9
 renin-secreting tumors of, 1614
 sodium absorption/excretion in, 64e-2f, 296–297, 296f, 297f, 332e-3–6f, 332e-10–11, 332e-10f
- uric acid metabolism in, 431e-1, 431e-2
 vasculature of, 332e-2, 332e-2f, 1627
 in vitamin D metabolism, 2464, 2464f
 water absorption/excretion by, 64e-2f, 295–296, 296f, 332e-3–6f, 332e-9–10, 332e-10f